Neil F. McFarlane

Neil F. McFarlane has served as a member of the Board of Managers of HCRx Holdings since January 2024. Mr. McFarlane is the President, Chief Executive Officer and member of the board of directors of Zevra Therapeutics. He previously served as the Chief Executive Officer and a member of the Board of Directors for Adamas Pharmaceuticals until November 2021, when Adamas was acquired by Supernus Pharmaceuticals. Prior to Adamas, Mr. McFarlane served as the Chief Operating Officer of Retrophin (now Travere Therapeutics). Prior to his position at Retrophin, Mr. McFarlane held positions of increasing responsibility with UCB, Genzyme (now Sanofi) and Sangstat Medical (acquired by Genzyme). Mr. McFarlane currently serves on the Board of Directors for Collegium Pharmaceuticals. He proudly served as an officer and enlisted soldier in the United States Army Reserves, and earned his B.S. and M.S. in Nursing from the University of Florida.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.